David Arnopole
Family · Medford, ORNPI 1720647225
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $28,500 of the $38,264 with a category attached, or 74.5%. 60 manufacturers reported payments, led by TG Therapeutics, Inc. at 24.3% of the total. 2025 is the largest year on record at $15,168, 2.8 times the $5,487 reported in 2022. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,146 payments — averaging $33.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$9K
- Biogen$3K
- AbbVie$3K
- EMD Serono, Inc.$2K
- UCB, Inc.$1K
- AstraZeneca$1K
- plus $18K from 54 others
What the payments were for
- Speaking & faculty fees$5,81315%
- Travel & lodging$3,4869%
- Food & beverage$28,50074%
- Education$4651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$8,771
- VNS Therapy$900
- PERCEPT PC BRAINSENSE$724
- Mavenclad$592
- ULTOMIRIS$336
- ENROUTE Transcarotid Neuroprotection System$271
- NUPLAZID$247
- KESIMPTA$234
- Leqembi$230
- INGREZZA$227
- VYVGART HYTRULO$219
- NURTEC ODT$138
- ZAVZPRET$138
- ENROUTE Transcarotid Stent$135
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$135
- Austedo XR$125
- Epidiolex$125
- AMVUTTRA$125
- ONPATTRO$125
- Rystiggo$125
How this compares
$38,264 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 27 | $150,618 |
| Austedo XrDeutetrabenazine | 20 | $107,840 |
| UbrelvyUbrogepant | 63 | $102,518 |
| Nurtec OdtRimegepant Sulfate | 53 | $96,886 |
| AustedoDeutetrabenazine | 12 | $80,525 |
| Emgality PenGalcanezumab-Gnlm | 64 | $67,687 |
| RytaryCarbidopa/Levodopa | 18 | $47,331 |
| FycompaPerampanel | 35 | $41,091 |
| Tetrabenazine | 13 | $39,674 |
| NuedextaDextromethorphan Hbr/Quinidine | 23 | $32,506 |
| BriviactBrivaracetam | 19 | $27,329 |
| Emgality SyringeGalcanezumab-Gnlm | 26 | $21,894 |
| QuliptaAtogepant | 14 | $18,767 |
| XcopriCenobamate | 14 | $18,377 |
| EpidiolexCannabidiol (Cbd) | 13 | $13,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $964 | $188,36532 claims |
| Acadia Pharmaceuticals IncNuplazid | $694 | $150,61827 claims |
| AbbVieUbrelvy, Qulipta | $2,793 | $121,28577 claims |
| PfizerNurtec Odt | $793 | $96,88653 claims |
| Amneal Pharmaceuticals LLCRytary | $34 | $47,33118 claims |
| Eisai Inc.Fycompa | $1,105 | $41,09135 claims |
| UCB, Inc.Briviact | $1,273 | $27,32919 claims |
| SK Life Science, Inc.Xcopri | $441 | $18,37714 claims |
| AstraZenecaBrilinta | $1,260 | $11,27217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in Medford
- Denise PartinMedford$7K
- Sarah RobersonMedford$4K
- Jody HaasMedford$3K
- Molly ThompsonMedford$3K
- Heather BascomMedford$3K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.